Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK?+?non-small cell lung cancer (ALTA-1L).
Garcia Campelo MR, Lin HM, Zhu Y, P?rol M, Jahanzeb M, Popat S, Zhang P, Camidge DR. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK?+?non-small cell lung cancer (ALTA-1L). Lung Cancer. 2021 05; 155:68-77.